Early Stage Endometrial Cancer: Adjuvant Treatment
|
|
|
- Lucas Carroll
- 7 years ago
- Views:
Transcription
1 Gynecologic Radiation Oncology Early Stage Endometrial Cancer: Adjuvant Treatment Fernanda Herrera M.D. Department of Radiation Oncology Centre Hospitalier Universitaire Vaudois
2 Outline Is there any subgroup of patients who do not need adjuvant irradiation? Is there any subgroup of patients for whom a brachytherapy treatment would be enough? Is there any subgroup of patients that will certainly need adjuvant pelvic RT +/- brachytherapy? Should we administered EBRT to those that did not received lymphadenectomy?
3 Endometrial Cancer Most common gynecological cancer 20 cases/ Postmenopausal women Obese Comorbide: DBT, HTA, etc. TAH-BSO LND is the cornerstone of treatment % of cases are confined to the uterus (early disease) 70% have low-intermediate risk features 30% have high risk features 15% will developed mtts disease.
4 Classification of Disease Categories Simple Risk Assessment Table Early Stage Stage IA (Glands inv only) Stage IB (<50% inv.) Stage IC (deeply invnow IB) G1 Low Low Interm. G2 Low Low Interm % LRR G3 Interm. Interm. High
5 Classification of Disease Categories GOG 33 (Creasman W. Cancer 1987/Morrow P. G&O1991) Probability of recurrence having a single risk factor: 1/3 myometrial inf: 15% Grade 3 tumors: 16% LVSI: 26% Cervix: 16% One risk factor: recurrence frequency of 20% Two risk factors: 40%
6 Classification of Disease Categories: GOG 33 Intermediate risk group: At least one of these features 20-25% risk of LRR >60 year old >50% myometrial inv. G3 LVSI
7 Does everyone needs adjuvant post-op radiation? Indication to be consider according to: Surgical stage Myometrial invasion Grade LVSI Histology Cervix Patient decision based on informed consent of risk benefit assessment
8 Intermediate Risk - Early Stages 5 Randomized Studies evaluating role of RT Aalders 1980 (Obstet Gynecol 56:419, 1980) GOG 99: Keys (Gynecol Oncol, 92:744, 2004) Portec-1: Creutzberg (Lancet 355:1404, 2000) MRC ASTEC/ NCIC EN5 (The Lancet 373:137, 2009) Portec-2: (The Lancet 375:816, 2010)
9 Keys et al GOG 99 (G&O 2004) Stage IB, IC, II (any grade) low-intermediate risk Excluded serous papillary and clear cell Groups well balanced. Analysis by ITT principle. 448 women entered TAH-BSO-LND (pelvic and PAO) + washing 31 ineligible 25 ineligible 190 pts EBRT 50.4 Gy (CO60 allowed) No Bq. 202 pts. NFT 1 endpoint: recurrence free survival
10 Keys et al GOG patients in 8 years. Median follow-up 69m Low-Intermediate risk: 82.3% inner and middle third invasion Only 17.6% outer third invasion 80% G1-2 High-intermediate risk: (⅓ of the patients accrued) G3, LVSI, outer 1/3 myometrial inv. 50 year old + 2 facteurs 70 year old + 1 facteur
11 Keys et al GOG 99 Recurrences Decreased HR for recurrences among those in RT arm. HR= 0.42 (90% CI ), P= RT: 3% (90% CI ) vs. NFT: 12% (90% CI )
12 GOG 99 - Low Intermediate Risk (Keys et al. GynOnc 92:744, 2004) Recurrence Overall survival % with recurrence Time (years) No RT RT % surviving Time (years)
13 GOG 99 - High Intermediate Risk (Keys et al. GynOnc 92:744, 2004) Recurrence Overall survival Pelvis RT % with recurrence No RT Pelvic RT Time (years) % surviving Time (years)
14 Keys et al GOG 99: Recurrence sites TAH-BSO ONLY POST-OP RT DM Vagina 7.4% DM DM+Pelvis Pelvis Vagina 1.06% Pelvis
15 Keys et al GOG 99 2 death due to GI toxicity in the RT arm (p<0.001) Significant diff. (p<0.001) in hematologic, genitourinary, gastrointestinal and cutaneous toxicities for those receiving RT. 6 bowel obstructions (G3-4) in the RT arm No significant diff. in lymphaoedema.
16 Keys et al GOG 99: Conclusions Adjunctive RT in early stage intermediate risk endometrial carcinoma decreases the risk of recurrence, but should be limited to patients whose risk factors fit this high intermediate risk definition.
17 Intermediate Risk - Early Stages 5 Randomized Studies evaluating role of RT Aalders 1980 (Obstet Gynecol 56:419, 1980) GOG 99: Keys (Gynecol Oncol, 92:744, 2004) Portec-1: Creutzberg (Lancet 355:1404, 2000) MRC ASTEC/ NCIC EN5 (The Lancet 373:137, 2009) Portec-2: (The Lancet 375:816, 2010)
18 Creutzberg et al: PORTEC-1 (Lancet 2000) TAH+BSO, no LND, washings recomm. Main characteristics: 715 pts randomized (10 NE) Median follow-up: 73 months Groups well balanced 1 endpoints : LRR & OS. 2 endpoints: morbidity & SV after relapse 354 Sx+RT (Linac 46Gy/2Gy fx. No bq) 4 NE 339 received RT 22 mayor violations 8 minor violations 354 were followed 361 NFT 355 NFT 6 mayor violations: got RT 2 minor violations 1 lost FU 360 were followed
19 Creutzberg et al: PORTEC-1 (Lancet 2000) Inclusion Criteria: >60 year old: 72% Low risk included: IB G2 = 30% Intermediate risk included: IB G3=10% IC G1-2=60% IC G3 excluded! LVSI 6% Seropap. et clear cells included (10 pts) No central pathology review upfront and done in 80% of pts. at the time of pub. Deep of inv? *20% unavailable for review
20 Creutzberg et al: PORTEC-1 (Lancet 2000) Locoregional recurrences at 5 y. LRR: 14% NFT vs. 4 % RT (p<0.001) Most recurrences were in the vaginal vault (73%). 5 pts. had simultaneous DM (10%). 9 pts. developed DM after the LRR (18%). 79% 2-yr survival after vaginal relapse
21 Creutzberg et al: PORTEC-1 (Lancet 2000) Overall survival at 5y. Idem 81% vs. 85% (p=0.31) 105 patients died Dead of disease 40% Intercurrent death: 61%
22 Creutzberg et al: PORTEC-1 Scholten et al., IJROBP 63:834 (2005) Local Recurrences Correlated with grade G3: 18% Risk of death from EC Correlated with grade G3 (16%) Persisted at multivariate analysis and stronger than myo inv % Local recurrence-free 569 pts with path review ( RT) 20 G3 (86 pts) 15 G2 (88 pts) 10 G1 (395 pts) 5 Remember: Deeply invasive G3 not eligible!!! 0 Time in years
23 Creutzberg et al: PORTEC-1 Significant toxicity with EBRT Acute toxicity G3: 60% of patients (mainly GI) Late complications: 25% vs. 6% (p<0.001) G1: 68% mainly GI G3-4: 2% bowel obstruction
24 Intermediate Risk - Early Stages 5 Randomized Studies evaluating role of RT Aalders 1980 (Obstet Gynecol 56:419, 1980) GOG 99: Keys (Gynecol Oncol, 92:744, 2004) Portec-1: Creutzberg (Lancet 355:1404, 2000) MRC ASTEC/ NCIC EN5 (The Lancet 373:137, 2009) Portec-2: (The Lancet 375:816, 2010)
25 MRC ASTEC Radiotherapy and NCIC EN.5 Trial (Lancet 2009) Adjuvant external beam radiotherapy (EBRT) in the treatment of endometrial cancer: results of the randomised MRC ASTEC and NCIC CTG EN.5 trials ASTEC ISRCTN EN.5 clinicaltrials.gov NCT
26 Trial design for ASTEC/EN.5 Surgery EN.5: July ASTEC: July % ATH BSO 29% ATH BSO PLN (median #12) High intermediate risk pathology RANDOMIZED 905 cases IC, IIA any grade IA-B G3 N+ or washings cases 452 cases No EBRT External beam RT 45 Gy 2% EBRT, 52% Brachytherapy 98% EBRT 68 deaths 67 deaths Analyzed by ITT principle Median follow-up: 58 months Primary endpoint: Overall survival Secondary endpoint: DSS, LRR, toxicity
27 ASTEC / EN.5 TRIAL The study was not controlled for adjuvant therapies in the observational arm
28 ASTEC / EN.5 TRIAL Main characteristics: Groups well balanced except for : 25% HR in the obs. arm vs. 20% Rxt Local path used (pathologists from 7 countries ) Endometrioide : 83% HR: 22% and IR:76% LVSI +: 25%
29 ASTEC / EN.5 TRIAL No significant differences in: OS (84% in both groups) 36% of death due to other causes. 60% of death due to endometrial cancer Disease specific survival (90% NFT vs. 89% EBRT) Recurrence free survival (84.7 NFT vs EBRT)
30 ASTEC / EN.5 TRIAL Cumulative incidence of isolated vaginal or pelvic initial recurrence 5 years cumulative incidence rate of 6.1% NFT vs. 3.2% EBRT HR=0.46; 95% CI , p=0.02) Absolute diff.: 2.9% (95%CI <0.1%-5.9%)
31 ASTEC / EN.5 TRIAL Significant toxicity with EBRT Acute: 57% vs. 27% Late: 61% vs. 45%
32 ASTEC / EN.5 There is no evidence that the effect of external beam radiotherapy is different in women who have had lymphadenectomy as part of primary surgery (test for interaction for overall survival = 0.79, for disease-specific survival p=0.22)».
33 ASTEC / EN.5 TRIAL Conclusions: EBRT: No evidence of OS, DFS, RFS improvement in the intermediate risk group Can we generalize results for high-risk group (>50% inv., G3, LVSI+)? Suggests that brachy could be enough for LC. Also for high risk? The # of pts. who had LND was small not allowing for firm conclusions regarding the interaction between RT and LND
34 Incidence of Vaginal recurrences at 5 years TAH-BSO NFT (%) EBRT (%) Aalders et al 14.7 (sx+bq) 6.6 (+BQ) GOG (no BQ) PORTEC (no BQ) ASTEC/EN (50% brachy) 3.2 (no BQ) With an estimated decrease in local relapse from 15% to 4%, 1 in 10 patients will benefit from the procedure
35 Intermediate Risk - Early Stages 5 Randomized Studies evaluating role of RT Aalders 1980 (Obstet Gynecol 56:419, 1980) GOG 99: Keys (Gynecol Oncol, 92:744, 2004) Portec-1: Creutzberg (Lancet 355:1404, 2000) MRC ASTEC/ NCIC EN5 (The Lancet 373:137, 2009) Portec-2: (The Lancet 375:816, 2010)
36 VBT (3 fx 7 Gy) vs. EBRT PORTEC-2 Nout et al Lancet 2010 Randomized, non inferiority study (non inferiority margin of 6% in vaginal recurrence) 427 patients Median follow-up: 2 years and 9 months
37 PORTEC-2 New classification of intermediate risk called: high intermediate risk >60 years old and IC (deeply inv.)-g1-2 or IB G3 All ages and: IIA (glandular only) G1-2-3 Only G3 with <50% myom. Inv. Att: >50% myometrial inv. and G3 or LVI+ were excluded.
38 PORTEC-2 No statistically significant differences: Rate of vaginal recurrences (0.9 EBRT vs. 2% VBQ) Locoregional control and overall survival Slightly but not significant increased on pelvic recurrences (3.6 vs 0.7%) Vaginal Recurrence P = 0.74 VBT EBRT Years since randomization
39 PORTEC-2 / QUALITY OF LIFE JCO pts. (81%), Follow-up 2,7 years. RT intestinal symptoms. Diarrhea (12,9% EBRT vs. 5,6% VBT) Fecal leakeage (8,7% EBRT vs. 1,7% VBT) Sexual life: no significant difference Conclusion: VBT = better Q of L Missing data: 19% non responders in the EBRT arm Impact of late vs. Acute quality of life not assesed
40 Conclusions: PORTEC-2 VBT is effective in ensuring vaginal control, with fewer gastrointestinal toxic effects than with EBRT. VBT should be the adjuvant treatment of choice for patients with endometrial carcinoma of high-intermediate risk. Att: High-intermediate risk for PORTEC is low risk for others
41 What is High Intermediate Risk? GOG High intermediate-risk G2-3 + LVSI + outer 1/3 50 YO + 2 features 70 YO + 1 feature PORTEC-2 High intermediate-risk IC, G1-2 + > 60 YO IB, G3 + >60 YO IIA + G1-2 IIA + G3 + inner 1/2 37
42 G3, >50% excluded Path review (357/427): Pelvic vs. VBT (PORTEC-2 Trial) G1 (48% 79%) G2 (44% 9%) 14% ineligible for trial (IBG1) Other issues: Reliability of depth estimates Incomplete F/U Underpowered Nout et al. Lancet 375:816, *14% unavailable for review
43 Other questions without answer? What is high-intermediate risk? How does LND influences the role of EBRT and QOL. Does modern radiotherapy improve side effects and increases therapeutic ratio? Role of chemotherapy in high risk and high intermediate risk? PORTEC 3: Pelvis RT vs. CRT + carbo taxol. GOG 249: Pelvis RT vs VBT + carbo taxol.
44 Creutzberg C. IJGC 2010
45 Current International Recommendations Low risk (IA, G1-2): Intermediate risk IB, G1-2 IA, G3? Observation VBT ***Take always in to account other prognostic factors like: LVI, age > 60 year old If HIGH RISK (deeply inv., G3, LVI+, papillary sereus, clear cell): PELVIS EBRT Stages according to FIGO 2009
Sentinel Lymph Node Mapping for Endometrial Cancer. Locke Uppendahl, MD Grand Rounds
Sentinel Lymph Node Mapping for Endometrial Cancer Locke Uppendahl, MD Grand Rounds Endometrial Cancer Most common gynecologic malignancy in US estimated 52,630 new cases in 2014 estimated 8,590 deaths
How To Compare The Effects Of A Hysterectomy And A Hysterectomy
A RANDOMIZED TRIAL COMPARING RADICAL HYSTERECTOMY AND PELVIC NODE DISSECTION VS SIMPLE HYSTERECTOMY AND PELVIC NODE DISSECTION IN PATIENTS WITH LOW RISK EARLY STAGE CERVICAL CANCER A Gynecologic Cancer
Carcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology
Carcinoma of the Cervix Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Treatment Treatment Microinvasive (Stage IA1): Simple (extrafascial) hysterectomy/cone
Endometrial Cancer. Ellen Jones MD PhD University of North Carolina
The Management of Endometrial Cancer Ellen Jones MD PhD University of North Carolina Disclosure I have no conflicts of interest to disclose. Learning Objectives Describe the epidemiology, clinical presentation,
Endometrial Cancer. William Small Jr., MD Professor of Radiation Oncology The Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Endometrial Cancer William Small Jr., MD Professor of Radiation Oncology The Robert H. Lurie Comprehensive Cancer Center of Northwestern University Learning Objectives: Discuss the role of radiation therapy
Endometrial Cancer Treatment
Endometrial Cancer Treatment January 2006 By Shelly Smits, RHIT, CCS, CTR mary by Ian Thompson, MD Data Source: Cancer registry information on uterine cancer diagnosed 1/1/2000 to 12/31/2004. Reason for
PRIMARY TREATMENT CLINICAL PRESENTATION INITIAL EVALUATION. Conclude procedure with/without lymph node dissection
INITIAL EVALUATION History and Physical CXR Pathology review 1 Labs Consider CA125, and pre-operative imaging of abdomen and pelvis Screen for Lynch Syndrome by family history or molecular testing CLINICAL
Re irradiation Using HDR Interstitial Brachytherapy for Locally Recurrent. Disclosure
Re irradiation Using HDR Interstitial Brachytherapy for Locally Recurrent Cervical lcancer Yasuo Yoshioka, MD Department of Radiation Oncology Osaka University Graduate School of Medicine Osaka, Japan
Radiation Therapy in Early Stage Endometrial Cancer: Update and Perspectives Arno J. Mundt MD Professor and Chair Department of Radiation Oncology
Radiation Therapy in Early Stage Endometrial Cancer: Update and Perspectives Arno J. Mundt MD Professor and Chair Department of Radiation Oncology University of California San Diego Radiation Therapy in
Chemotherapy in Ovarian Cancer. Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group
Chemotherapy in Ovarian Cancer Dr R Jones Consultant Medical Oncologist South Wales Gynaecological Oncology Group Adjuvant chemotherapy for early stage EOC Fewer than 30% women present with FIGO stage
Prostatectomy, pelvic lymphadenect. Med age 63 years Mean followup 53 months No other cancer related therapy before recurrence. Negative.
Adjuvante und Salvage Radiotherapie Ludwig Plasswilm Klinik für Radio-Onkologie, KSSG CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTS 1983 1998 Clinical stage T1 and T2 Mean
The Role of Laparoscopy in Endometrial Cancer
The Role of Laparoscopy in Endometrial Cancer Prof. Dr. Tugan BEŞE İstanbul University, Cerrahpaşa Medical Faculty Gynecologic Oncology Department Surgical staging in Endometrial Cancer Laparoscopic surgery
Stomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda
Stomach (Gastric) Cancer Prof. M K Mahajan ACDT & RC Bathinda Gastric Cancer Role of Radiation Layers of the Stomach Mucosa Submucosa Muscularis Serosa Stomach and Regional Lymph Nodes Stomach and Regional
Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs. Case Study. Surgery. Lumpectomy and Radiation
Management of Postmenopausal Women with T1 ER+ Tumors: Options and Tradeoffs Michael Alvarado, MD Associate Professor of Surgery University of California San Francisco Case Study 59 yo woman with new palpable
How To Treat A Uterine Sarcoma
EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4 th Edition 2001 Uterus: Uterine Sarcomas Jeffrey L. Stern, MD Uterine sarcomas
Understanding Your Diagnosis of Endometrial Cancer A STEP-BY-STEP GUIDE
Understanding Your Diagnosis of Endometrial Cancer A STEP-BY-STEP GUIDE Introduction This guide is designed to help you clarify and understand the decisions that need to be made about your care for the
Invasive Cervical Cancer. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology
Invasive Cervical Cancer Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Etiology Human Papilloma Virus (HPV): Detected in 99.7% of cervical cancers Cancer
How TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer
How TARGIT Intra-operative Radiotherapy can help Older Patients with Breast cancer Jeffrey S Tobias, Jayant S Vaidya, Frederik Wenz and Michael Baum, University College Hospital, London, UK - on behalf
Surgical Staging of Endometrial Cancer
Surgical Staging of Endometrial Cancer I. Endometrial Cancer Surgical Staging Overview Uterine cancer types: carcinomas type I and type II, sarcomas, carcinosarcomas Hysterectomy with BSO Surgical Staging
Special Article. Received 2 December 2013; accepted 15 January 2014. Practical Radiation Oncology (2014) 4, 137 144. www.practicalradonc.
Practical Radiation Oncology (2014) 4, 137 144 www.practicalradonc.org Special Article The role of postoperative radiation therapy for endometrial cancer: Executive Summary of an American Society for Radiation
The evolution of rectal cancer therapy. Objectives
The evolution of rectal cancer therapy Hagen Kennecke MD MHA FRCPC Western Canada Consensus Conference September 5, 2014 Objectives Identify standard therapy: stage II/III rectal cancer Update recent adjuvant
Endometrial Cancer. Measurability of Quality Performance Indicators Version 2.0
Endometrial Cancer Measurability of Quality Performance Indicators Version 2.0 To be read in conjunction with: Endometrial Cancer QPIs Final Publication v2 Endometrial QPI Dataset (latest published version)
7. Prostate cancer in PSA relapse
7. Prostate cancer in PSA relapse A patient with prostate cancer in PSA relapse is one who, having received a primary treatment with intent to cure, has a raised PSA (prostate-specific antigen) level defined
Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France
Should we use Docetaxel in hormone- naïve prostate cancer? Karim Fizazi, MD, PhD Institut Gustave Roussy Villejuif, France Disclosure Participation to advisory boards/honorarium from: Amgen, Astellas,
Management of low grade glioma s: update on recent trials
Management of low grade glioma s: update on recent trials M.J. van den Bent The Brain Tumor Center at Erasmus MC Cancer Center Rotterdam, the Netherlands Low grades Female, born 1976 1 st seizure 2005,
Nursing Care of the Patient Receiving Brachytherapy for Gynecologic Cancer
Nursing Care of the Patient Receiving Brachytherapy for Gynecologic Cancer Una Randall, RN, BSN, OCN Dana Farber / Brigham and Women s Cancer Center Department of Radiation Oncology Una Randall is not
Endometrial Cancer. GYNE/ONC Practice Guideline. Approval Date: February 2011 V2.3 converted file format
Endometrial Cancer GYNE/ONC Practice Guideline Approval Date: February 2011 V2.3 converted file format This guideline is a statement of consensus of the Gynecologic Oncology Disease Site Team regarding
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group
Komorbide brystkræftpatienter kan de tåle behandling? Et registerstudie baseret på Danish Breast Cancer Cooperative Group Lotte Holm Land MD, ph.d. Onkologisk Afd. R. OUH Kræft og komorbiditet - alle skal
La personalizzazione terapeutica: quanto influisce l età
La personalizzazione terapeutica: quanto influisce l età PierFranco Conte University of Padova Department of Surgery, Oncology and Gastroenterology IOV Istituto Oncologico Veneto I.R.C.C.S. Breast Cancer
Overview of Gynaecologic Cancer
Overview of Gynaecologic Cancer Stuart Salfinger Gynaecologic Oncologist St John of God Hospital King Edward Memorial Hospital Cervical Cancer Cervical Cancer Risk HPV Smoking?OCP Cervical Cancer Symptoms
La Chemioterapia Adiuvante Dose-Dense. Lo studio GIM 2. Alessandra Fabi
La Chemioterapia Adiuvante Dose-Dense Lo studio GIM 2 Alessandra Fabi San Antonio Breast Cancer Symposium -December 10-14, 2013 GIM 2 study Epirubicin and Cyclophosphamide (EC) followed by Paclitaxel (T)
Transition from 2D to 3D Brachytherapy in Cervical Cancers: The Vienna Experience. Richard Pötter MD. BrachyNext, Miami, 2014.
Transition from 2D to 3D Brachytherapy in Cervical Cancers: The Vienna Experience Richard Pötter MD BrachyNext, Miami, 2014 Disclosures Richard Pötter, MD, does not have any financial relationships or
Monthly palliative pelvic radiotherapy in advanced carcinoma of uterine cervix
Original Article Free full text available from www.cancerjournal.net Monthly palliative pelvic radiotherapy in advanced carcinoma of uterine cervix Mishra Sanjib K, Laskar Siddhartha, Muckaden Mary Ann,
The Role of Adjuvant Therapy in Endometrial Cancer
No. 290, April 2013 The Role of Adjuvant Therapy in Endometrial Cancer This clinical practice guideline has been prepared by the SOGC-GOC-SCC Policy and Practice Guidelines Committee and approved by the
INTERVENTIONAL PROCEDURES PROGRAMME
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE INTERVENTIONAL PROCEDURES PROGRAMME Interventional procedure overview of radical laparoscopic hysterectomy for early stage cervical cancer Introduction This overview
Cancer research in the Midland Region the prostate and bowel cancer projects
Cancer research in the Midland Region the prostate and bowel cancer projects Ross Lawrenson Waikato Clinical School University of Auckland MoH/HRC Cancer Research agenda Lung cancer Palliative care Prostate
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center
Laparoscopic hysterectomy with or without pelvic. lymphadenectomy or sampling in a high-risk series of
Laparoscopic hysterectomy with or without pelvic lymphadenectomy or sampling in a high-risk series of patients with endometrial cancer Susan F Willis Thomas EJ Ind * Desmond Barton Department of Gynaecological
An Intergroup trial of the Dutch Cooperative Gynecologic Oncology Group and the UK National Cancer Research Institute
Randomized Phase III Trial Comparing Concurrent Chemoradiation and Adjuvant Chemotherapy with Pelvic Radiation Alone in High Risk and Advanced Stage Endometrial Carcinoma: PORTEC-3 An Intergroup trial
The Science behind Proton Beam Therapy
The Science behind Proton Beam Therapy Anthony Zietman MD Shipley Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School Principles underlying Radiotherapy Radiation related
Radiotherapy in locally advanced & metastatic NSC lung cancer
Radiotherapy in locally advanced & metastatic NSC lung cancer Dr Raj Hegde. MD. FRANZCR Consultant Radiation Oncologist. William Buckland Radiotherapy Centre. Latrobe Regional Hospital. Locally advanced
Radiation Therapy for Prostate Cancer: Treatment options and future directions
Radiation Therapy for Prostate Cancer: Treatment options and future directions David Weksberg, M.D., Ph.D. PinnacleHealth Cancer Institute September 12, 2015 Radiation Therapy for Prostate Cancer: Treatment
Current Status and Perspectives of Radiation Therapy for Breast Cancer
Breast Cancer Current Status and Perspectives of Radiation Therapy for Breast Cancer JMAJ 45(10): 434 439, 2002 Masahiro HIRAOKA, Masaki KOKUBO, Chikako YAMAMOTO and Michihide MITSUMORI Department of Therapeutic
Outcome of Early Cervical Carcinoma Treated by Wertheim Hysterectomy with Selective Postoperative Radiotherapy
ORIGINAL ARTICLES 613 Outcome of Early Cervical Carcinoma Treated by Wertheim Hysterectomy with Selective Postoperative Radiotherapy S K Tay,*FAMS, MD, FRCOG, L K Tan,**MBBS, M Med (O & G), MRCOG Abstract
Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases
I Congresso de Oncologia D Or July 5-6, 2013 Integrating Chemotherapy and Liver Surgery for the Management of Colorectal Metastases Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University
the standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009
Mesothelioma: The standard of care Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009 take home messages PILC 2006 All patients should receive adequate palliation of dyspnea and pain before starting chemotherapy
U.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
Loco-regional Recurrence
Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer AGO AGO e. e. V. V. Loco-regional Recurrence Loco-regional Recurrence Version 2002: Brunnert / Simon Versions 2003 2012: Audretsch
Role of Robotic Surgery in Obese Women with Endometrial Cancer
Role of Robotic Surgery in Obese Women with Endometrial Cancer Anil Tailor Consultant Gynaecological Oncologist Royal Surrey County Hospital Guildford, Surrey, UK St Peters Hospital Chertsey, Surrey, UK
Progress and Prospects in Ovarian Cancer Screening and Prevention
Progress and Prospects in Ovarian Cancer Screening and Prevention Rebecca Stone, MD MS Assistant Professor Kelly Gynecologic Oncology Service The Johns Hopkins Hospital 1 No Disclosures 4/12/2016 2 Ovarian
GYNECOLOGIC CANCERS Facts to Help Patients Make an Informed Decision
RADIATION THERAPY FOR GYNECOLOGIC CANCERS Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY FACTS ABOUT GYNECOLOGIC CANCERS Gynecologic cancers
Total laparoscopic hysterectomy for endometrial cancer: patterns of recurrence and survival
Gynecologic Oncology 92 (2004) 789 793 www.elsevier.com/locate/ygyno Total laparoscopic hysterectomy for endometrial cancer: patterns of recurrence and survival Andreas Obermair, a,b, * Tom P. Manolitsas,
THE SECRETS OF OUR SUCCESS
THE SECRETS OF OUR SUCCESS QUALITY OF LIFE STUDIES OF THE NCIC Andrea Bezjak, MDCM, MSc,, FRCPC Chair, NCIC CTG QOL Committee Outline of the Presentation Can we consider NCIC CTG QOL activities a success?
Treatment Volume and Technique
RADIATION THERAPY The standard of care for early lesions is surgical resection; however, selected patients with small central lesions may be considered for definitive radiation, particularly when the lesions
Rectal Cancer. To Radiate or not to radiate? Q: Should rectal cancer RT/CRT decisions be based solely on stage? 11/09/2014
Rectal Cancer To Radiate or not to radiate?? Dr. Corinne Doll Radiation Oncologist Tom Baker Cancer Centre Calgary, Alberta Q: Should rectal cancer RT/CRT decisions be based solely on stage? 1 Q: Can RT/CRT
New strategies in anticancer therapy
癌 症 診 療 指 引 簡 介 及 臨 床 應 用 New strategies in anticancer therapy 中 山 醫 學 大 學 附 設 醫 院 腫 瘤 內 科 蔡 明 宏 醫 師 2014/3/29 Anti-Cancer Therapy Surgical Treatment Radiotherapy Chemotherapy Target Therapy Supportive
CANCER PULMON: ESTADIOS INICIALES POSTMUNDIAL PULMON DENVER 2015. 8-10-2015.Manuel Cobo Dols S. Oncología Médica HU Málaga Regional y VV
CANCER PULMON: ESTADIOS INICIALES POSTMUNDIAL PULMON DENVER 2015 8-10-2015.Manuel Cobo Dols S. Oncología Médica HU Málaga Regional y VV Meta-analisis LACE: adyuvancia vs no adyuvancia Pignon JP, et al.
CHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER. Walter Stadler, MD University of Chicago
CHEMOTHERAPY FOR ADVANCED UROTHELIAL CANCER OF THE BLADDER Walter Stadler, MD University of Chicago Chemotherapy Doctor Terms Drugs used to treat cancer Will attack cancer no matter where it is located
RESEARCH ARTICLE. Abstract. Introduction. Materials and Methods
DOI:http://dx.doi.org/10.7314/APJCP.2015.16.13.5483 Perioperative and Oncologic Outcomes with Laparotomy, and Laparoscopic, and Robotic Surgery for Endometrial Cancer RESEARCH ARTICLE Comparison of Perioperative
Gynecologic Cancer in Women with Lynch Syndrome
Gynecologic Cancer in Women with Lynch Syndrome Sarah E. Ferguson, MD FRCSC Division of Gynecologic Oncology, Princess Margaret Hospital, University of Toronto June 11, 2013 Objective 1. To review the
Protons vs. CyberKnife. Protons vs. CyberKnife. Page 1 UC SF. What are. Alexander R. Gottschalk, M.D., Ph.D.
Protons vs. CyberKnife UC SF Protons vs. CyberKnife UC SF Alexander R. Gottschalk, M.D., Ph.D. Associate Professor and Director of the CyberKnife Radiosurgery Program Department of Radiation Oncology University
Endometrial cancer-carcinoma of the lining of the uterus-is the most common gynecologic
EVERYONE S GUIDE FOR CANCER THERAPY Malin Dollinger, MD, Ernest H. Rosenbaum, MD, Margaret Tempero, MD, and Sean Mulvihill, MD 4th Edition 2001 Uterus: Endometrial Carcinoma Jeffrey L. Stern, MD Endometrial
Luis D. Carcorze Soto, MD PGY-3
Luis D. Carcorze Soto, MD PGY-3 Peritoneal Surface Malignancies Peritoneum Patient Selection Operative Technique HIPEC EPIC Primary: Primary Peritoneal Carcinoma Malignant Peritoneal Mesothelioma Metastatic:
Cervical Cancer: Definitive Chemoradiation
Cervical Cancer: Definitive Chemoradiation Huma Chaudhry Jordan Kharofa Faculty: Dr. Beth Erickson, MD Medical College of Wisconsin Department of Radiation Oncology July 14, 2013 Clinical Presentation
CYBERKNIFE RADIOSURGERY FOR EARLY PROSTATE CANCER Rationale and Results. Alan Katz MD JD Flushing, NY USA
CYBERKNIFE RADIOSURGERY FOR EARLY PROSTATE CANCER Rationale and Results Alan Katz MD JD Flushing, NY USA Prostate Ablative Therapy Over the last 10 years our therapy has improved bned rates for LDR/HDR
What is neuroendocrine cervical cancer?
Key Points: 1. Neuroendocrine cancer of the uterine cervix is a rare and aggressive disease. 2. Treatment for neuroendocrine cervical cancer is usually more intensive than that for most other types of
NATIONAL CANCER DRUG FUND PRIORITISATION SCORES
NATIONAL CANCER DRUG FUND PRIORITISATION SCORES Drug Indication Regimen (where appropriate) BORTEZOMIB In combination with dexamethasone (VD), or with dexamethasone and thalidomide (VTD), is indicated
Maintenance therapy in in Metastatic NSCLC. Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai
Maintenance therapy in in Metastatic NSCLC Dr Amit Joshi Associate Professor Dept. Of Medical Oncology Tata Memorial Centre Mumbai Definition of Maintenance therapy The U.S. National Cancer Institute s
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials)
ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials) 3 Integrated Trials Testing Targeted Therapy in Early Stage Lung Cancer Part of NCI s Precision Medicine Effort in
TITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software.
SAMPLE CLINICAL RESEARCH APPLICATION ABSTRACT: TITLE: Comparison of the dosimetric planning of partial breast irradiation with and without the aid of 3D virtual reality simulation (VRS) software. Hypothesis:
Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
PRIMARY GLIOMA (oligodendroglioma, astrocytoma, oligodendroglioma, oligoastrocytoma, including anaplastic, gliosarcoma and glioblastoma multiforme)
Protocol for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: PRIMARY GLIOMA (oligodendroglioma, astrocytoma, oligodendroglioma, oligoastrocytoma, including
Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50
General Data Seton Medical Center Hepatocellular Carcinoma Patterns of Care Study Rate of Treatment with Chemoembolization 2007 2012 N = 50 The vast majority of the patients in this study were diagnosed
Basics and limitations of adjuvant online an internet based decision tool
Basics and limitations of adjuvant online an internet based decision tool J. Huober SAKK, Bern 31.10.2013 Univ.-Frauenklinik Ulm Integratives Tumorzentrum des Universitätsklinikums und der Medizinischen
HER2 Status: What is the Difference Between Breast and Gastric Cancer?
Ask the Experts HER2 Status: What is the Difference Between Breast and Gastric Cancer? Bharat Jasani MBChB, PhD, FRCPath Marco Novelli MBChB, PhD, FRCPath Josef Rüschoff, MD Robert Y. Osamura, MD, FIAC
Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.
Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited
Radioterapia panencefalica. Umberto Ricardi
Radioterapia panencefalica Umberto Ricardi Background Systemic disease to the brain is unfortunately a quite common event Radiotherapy, especially with the great technical development during the past decades,
American Urological Association (AUA) Guideline
1 (AUA) Guideline Approved by the AUA Board of Directors April 2013 Authors disclosure of potential conflicts of interest and author/staff contributions appear at the end of the article. 2013 by the American
Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
Clinical Trials and Radiation Treatment. Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto
Clinical Trials and Radiation Treatment Gerard Morton Odette Cancer Centre Sunnybrook Research Institute University of Toronto What I will cover.. A little about radiation treatment The clinical trials
Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate e P rofessor Professor Radiation Oncology
Principles of Radiation Therapy A Bapsi Chakravarthy, MD Associate Professor Radiation Oncology Disclosure Information I have no financial relationships to disclose relevant to the conten of this presentation.
SCAN Gynaecological Group. Clinical Management Protocols: Cancer of the Cervix. www.scan.scot.nhs.uk
SE Scotland Cancer Network SCAN Gynaecological Group Clinical Management Protocols: Cancer of the Cervix www.scan.scot.nhs.uk Table of contents 3 Introduction 4 Diagnosis 5-6 Staging and spread of disease
Corporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: hematopoietic_stem-cell_transplantation_for_epithelial_ovarian_cancer 2/2001 11/2015 11/2016 11/2015 Description
Radiotherapy in Plasmacytoma and Myeloma. David Cutter Multiple Myeloma NSSG Annual Meeting 14 th September 2015
Radiotherapy in Plasmacytoma and Myeloma David Cutter Multiple Myeloma NSSG Annual Meeting 14 th September 2015 Contents Indications for radiotherapy: Palliation in Multiple Myeloma Solitary Bone Plasmacytoma
Safe and Effective Surgery for Endometriosis Including Detection and Intervention for Ovarian Cancer
Safe and Effective Surgery for Endometriosis Including Detection and Intervention for Ovarian Cancer Camran Nezhat,, MD, FACOG, FACS Stanford University Medical Center Center for Special Minimally Invasive
Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka
Adiuwantowe i neoadiuwantowe leczenie chorych na zaawansowanego raka żołądka Neoadiuvant and adiuvant therapy for advanced gastric cancer Franco Roviello, IT Neoadjuvant and adjuvant therapy for advanced
Approccio multidisciplinare nei tumori del retto
Approccio multidisciplinare nei tumori del retto F. Muñoz Radiation Oncology Department University of Torino, Italy RECENT CHANGES IN RECTAL CANCER DIAGNOSIS AND THERAPY Optimal staging by EUS and MRI
Table of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation
PCa Commentary. Volume 73 January-February 2012 PSA AND TREATMENT DECISIONS:
1101 Madison Street Suite 1101 Seattle, WA 98104 P 206-215-2480 www.seattleprostate.com PCa Commentary Volume 73 January-February 2012 CONTENTS PSA SCREENING & BASIC SCIENCE PSA AND TREATMENT 1 DECISIONS
Hodgkin Lymphoma Disease Specific Biology and Treatment Options. John Kuruvilla
Hodgkin Lymphoma Disease Specific Biology and Treatment Options John Kuruvilla My Disclaimer This is where I work Objectives Pathobiology what makes HL different Diagnosis Staging Treatment Philosophy
Malignant Mesothelioma State of the Art
Malignant Mesothelioma State of the Art Paul Baas The Netherlands Cancer Institute August 12, 2011, Carlsbad, CA Summary Diagnosis; epithelial type subdivided Pleiomorphic vs other Staging: IASLC-IMIG
RADIATION THERAPY FOR BLADDER CANCER. Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY
RADIATION THERAPY FOR Facts to Help Patients Make an Informed Decision TARGETING CANCER CARE AMERICAN SOCIETY FOR RADIATION ONCOLOGY FACTS ABOUT The bladder is located in the pelvis. It collects and stores
These rare variants often act aggressively and may respond differently to therapy than the more common prostate adenocarcinoma.
Prostate Cancer OVERVIEW Prostate cancer is the second most common cancer diagnosed among American men, accounting for nearly 200,000 new cancer cases in the United States each year. Greater than 65% of
Understanding INTRABEAM Intraoperative Radiation Therapy for Breast Cancer A patient guide
Understanding INTRABEAM Intraoperative Radiation Therapy for Breast Cancer A patient guide A diagnosis of breast cancer is never easy, but today there are more treatment options than ever before. A breast
Clinical Trial Endpoints for Regulatory Approval First-Line Therapy for Advanced Ovarian Cancer
Clinical Trial Endpoints for Regulatory Approval First-Line Therapy for Advanced Ovarian Cancer Elizabeth Eisenhauer MD FRCPC Options for Endpoints First-Line Trials in Advanced OVCA Overall Survival:
Recurrence of cancer cervix in patients treated by radical hysterectomy followed by adjuvant external beam radiotherapy
Bangladesh Med Res Counc Bull 2010; 36: 52-56 Recurrence of cancer cervix in patients treated by radical hysterectomy followed by adjuvant external beam radiotherapy Fauzia Sobhan 1, Farzana Sobhan 2,
2 Laparoscopic hysterectomy in endometrial cancer
Laparoscopic hysterectomy in endometrial cancer .1 Total laparoscopic hysterectomy versus abdominal hysterectomy in the treatment of patients with early stage endometrial cancer: A randomized multi center
Breast Cancer Educational Program. June 5-6, 2015
Breast Cancer Educational Program June 5-6, 2015 Adjuvant Systemic Therapy For Early Breast Cancer: Who, What and for How Long? Debjani Grenier MD, FRCPC Medical Oncologist Disclosures Advisory Board Member:
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
Robert Bristow MD PhD FRCPC
Robert Bristow MD PhD FRCPC Clinician-Scientist and Professor, Radiation Oncology and Medical Biophysics, University of Toronto and Ontario Cancer Institute/ (UHN) Head, PMH-CFCRI Prostate Cancer Research